Search Results

Nyla Naim, Dr. Michael Lemieux & Dr. Jason Nasse About Dr. Nyla Naim Nyla is a Senior Scientist on the Scientific Support Team at Addgene . Nyla supports biomedical research by connecting researchers with resources and promoting reproducible Nyla Naim on the web LinkedIn Dr. GPCR Ecosystem About Dr.

Nicolas Gilles is an expert in the study of animal toxins. He is pioneering the investigation of animal toxins acting on GPCRs, the largest therapeutic target class

moment of her scientific life was designing a compound in a HEK cell from a hypothesis, putting it in an animal moment was designing a compound in HEK293 cells from a hypothesis at Novo Nordisk, putting it in an animal 25:26 — The HEK293 experiment that predicted the animal 31:21 — Tools for the next decade: biosensors

altered, and that drug candidates fail in clinical trials partly because they are validated in naïve animals Her next career step took her to AstraZeneca as a postdoctoral trainee, where she studied animal models Andrew Charles that who specialized in animal models of migraine and delta-opioid receptors as a therapeutic

Allosteric modulation and non-orthosteric binding sites on GPCRs Biased agonism, target validation, and animal-to-human Marshall's caution is hard-won: many animal-model-validated GPCR drugs have failed in the clinic precisely the next wave of GPCR drug design 18:47 Which GPCR families pharma is chasing now — and why 21:23 Why animal

I work with invertebrate animal models (mainly D. melanogaster) and in vitro techniques to pick apart

Critically, these ligands reduce addiction-associated behaviors in animal models without the side effects

combines bioinformatic analysis of GPCR expression across human cancers with wet-lab validation in animal since studied receptor function in human physiology, receptor molecular pharmacology in cells, and animal

Critically, these ligands reduce addiction-associated behaviors in animal models without the side effects

From struggling to grip mice in early animal studies to thesis delays during COVID-19, Serafini's journey

. - Arthur will work on designing ligands for specific receptors, aiming to create biased agonists for They also discussed the potential of certain drugs, like flumazenil, as 'nails' or compounds that could

function, and identifying renal/cardiovascular olfactory receptor ligands, and relating them to whole-animal

discussion about the importance of gaining more information about the therapeutic effect in patients or animals

His lab combines cell and molecular biology with animal pharmacology to identify new signaling regulators